Christopher Fuglesang - Profile and Investment Details

Investor Profile

Christopher Fuglesang is a Venture Capital. based in San Diego, United States. with a diverse investment portfolio that includes companies such as Black Diamond Therapeutics, AveXis, Aligos Therapeutics, Tyra Biosciences, Encoded Therapeutics, Nabriva Therapeutics, Cullinan Oncology, Silverback Therapeutics, Telesta Therapeutics, Prevail Therapeutics, Nuvation Bio, Scorpion Therapeutics, PMV Pharmaceuticals, Cabaletta Bio, Attune Pharmaceuticals, Pandion Therapeutics, CiVi Biopharma, GTx, Vividion Therapeutics, Akero Therapeutics, Codiak Biosciences, Elevation Oncology, Atreca, Asher Bio, Sojournix, Cedilla Therapeutics, G1 Therapeutics, Shoreline Biosciences, Solid Biosciences, Milestone Pharmaceuticals, Passage Bio, Centessa Pharmaceuticals, Biomea Fusion, BioAtla, Poseida Therapeutics, MEI Pharma, Achilles Therapeutics, Kinnate Biopharma, Day One Biopharmaceuticals, Revolution Medicines, Boundless Bio, Rain Therapeutics, IDEAYA Biosciences, Mereo Biopharma, ITeos Therapeutics, Nurix Therapeutics, Syndax Pharmaceuticals, Tango Therapeutics, Connect Biopharmaceuticals, Vivace Therapeutics.. Over time, Christopher Fuglesang has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Christopher Fuglesang is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Women Founded, Women Led, Life Science, Information Technology (IT), Biotech, Healthcare, Biotechnology, Travel, Medical, Therapeutics, Pharmaceuticals, Biopharma. may find it worthwhile to explore potential connections with Christopher Fuglesang, as their portfolio suggests a familiarity and interest in this area.

Understanding Christopher Fuglesang’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.